Dorrance et al. demonstrated a successful miR-126 targeting by the transferrin or anti-CD45.2 antibody-conjugated nanoparticles containing antagomiR-126 both in vitro, in CD34+ blasts sorted from primary elderly AML patients, and in vivo, using Mll PTD Flt3 ITD mouse model [185]. This evidence concerns the gene FLT3 and acute myeloid leukemia.